News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL February 22, 2022
General News Regulated Oxurion NV announces 2021 Full Year Results and 2022 Outlook EN NL February 22, 2022
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL December 30, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA EN NL November 30, 2021
General News Regulated OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures EN November 22, 2021
News Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following conversion notices NEGMA EN NL November 3, 2021
General News Regulated OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN September 30, 2021
General News Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN January 20, 2021
General News Regulated OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices EN November 9, 2020
General News Regulated Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer EN October 13, 2020
General News Regulated Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 9, 2020
General News Regulated Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 5, 2020
General News Regulated Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME EN January 7, 2020
General News Regulated Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME EN December 19, 2019
